Viralytics targets cash injection for cancer research
Viralytics' (ASX:VLA) lead drug CAVATAK® harnesses the common cold virus to infect and kill cancer cells, with a market-leading body of clinical evidence across multiple cancer indications.
A global opportunity is currently being unlocked via a combination with leading in-market immunotherapies (KEYTRUDA® and YERVOY®) creating a clear path to market in area of high unmet need.
To advance the next steps, Viralytics is heading to market with a capital raising, and the ASX has granted the company a trading halt to prepare.
The halt will remain in place until the opening of trade on Monday 8th January 2018, or earlier if an announcement is made to the market.